

REMARKS

With this response, claims 1-18 are pending.

The present invention relates to certain novel 4-amino-2-butenoyl chlorides, processes for their preparation and their use as intermediates in the synthesis of pharmaceutically active protein kinase inhibitors.

Rejection Under 35 U.S.C. § 102

Claims 1-4 were rejected under 35 U.S.C. § 102, as being anticipated (paper no./Mail Date 042905, page 2).

Claim 1 has been amended to remove the compounds disclosed in the cited *J. of Medicinal Chemistry* (2003), Vol. 46, p. 49-63. Claims 2 and 3 have been canceled.

Claims 10-18 were rejected under 35 U.S.C. § 102, as being anticipated (paper no./Mail Date 042905, page 2).


Claim 10 has been amended to remove the compounds disclosed in the cited *J. of Medicinal Chemistry* (2003), Vol. 46, p. 49-63. Claim 11 has been canceled.

Claims 1-6 were rejected under 35 U.S.C. § 102, as being anticipated (paper no./Mail Date 042905, page 3).

Claim 1 has been amended to remove the compounds disclosed in the cited *U.S. patent 6,617,333 B2*. Claims 2 and 3 have been canceled.

It is believed that for the reasons stated above the present application is in condition for allowance and respectfully request that the Examiner allow the application.

A transmittal and a Petition for Extension of Time is attached.



Joy S. Goudie
Attorney for Applicants
Reg. No. 48,146

Wyeth
Patent Law Department
Five Giralda Farms
Madison, NJ 07940
Tel. No. (845) 602-2126